Lupin launches new generic drug in US market

Mumbai, April 22 (IANS) Pharma major Lupin Limited announced on Monday that it has launched Mirabegron extended-release tablets, 25 mg, in the United States market, after having received approval from the United States Food and Drug Administration (U.S. FDA).

Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq®Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc, the Mumbai-headquartered company said.

Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of USD 1,019 million in the US, market, according to the Lupin statement.

The company develops and commercialises a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions, the statement added.

–IANS

sps/dan

Share this article
0
Share
Shareable URL
Prev Post

Siachen no ordinary land but India’s capital when it comes to valour, sacrifice and courage: Rajnath Singh

Next Post

Pine Labs-owned Setu appoints ex-SAP India executive Anand Raisinghani as CEO

Read next
Whatsapp Join